NOVARTIS

CONSULTANCY AGREEMENT

This consultancy agreement is effective from ("**Effective Date**") February 14, 2025

BETWEEN:

(1) Novartis Pharma AG, a company organized and registered under the laws of Switzerland with registered office at Lichtstrasse 35, CH-4056 Basel, Switzerland,

Hereafter referred to as the "**Company**";

AND:

(2) **Lung Cancer Patient Association**, an organisation registered under the laws of Denmark with registered office at Secretariat Industrivej, 21, 4000 Roskilde, Denmark represented by Lisbeth Hansen, who shall perform the services in compliance with the obligations under this Agreement, on behalf of Lung Cancer Patients Foundation,

Hereafter referred to as the "**Consultant**";

The Company and the Consultant are hereafter jointly referred to as "**Parties**" and individually as "**Party**".

WHEREAS:

The Company is an international pharmaceutical company active in the field of research, development and commercialization of pharmaceuticals and medicinal products.

The Consultant is a reputable patient organization/ private practice delegating a Representative (as defined below), who has comprehensive expertise and experience in the field of health and patient advocacy, e.g., as an individual patient, caregiver, patient advocate, patient organization representative or patient expert.

The Company wishes to engage the services of the Consultant to provide the services set forth below, and the Consultant wishes to provide such services. The services are provided for the purpose of supporting healthcare and/or research.

It is specified that the Company respects the mission, autonomy and independence of the Consultant and any patient organization associated with and does not seek to exert any improper influence on their objectives, activities or decisions.

NOW, THEREFORE IT IS AGREED AS FOLLOWS:

1. Definitions

Affiliate: any company, organization, subsidiary or other business entity that is formally attached to, legally connected to the Company, or indirectly controlling, controlled by or under common control with a Party to this Agreement. "Control" shall mean the power to directly or indirectly, appoint a majority of the directors, or to otherwise direct or cause the direction of the management or polices of such company or entity whether through shared ownership, by contract or otherwise. For clarity, "Affiliate" shall also include but not be limited to Novartis Institutes for BioMedical Research, Inc.

Confidential Information: all non-public and business-related information, such as, but not limited to commercially sensitive information, strategic plans or processes, unpublished scientific data, planned public

campaigns or policy actions, draft project plans or concepts, written or oral, disclosed or made available to either Party, directly or indirectly, by or on behalf of one Party or its Affiliates (in the case of the Company) through any means of communication or observation.

Fees: the compensation paid for the services performed by the Consultant to the Company as specified under Appendix 1, exclusive of the expenses such as travel costs.

Services: general consultancy and advisory services provided to the Company by the Consultant as set out in Appendix 1.

2. Services

The Consultant shall provide the Services to the Company as set out under Appendix 1.

The content of the Services may be amended by mutual written agreement between the Parties.

2.1 Except as expressly provided otherwise in this Agreement, all rights, benefits, and obligations granted to Company under this Agreement shall extend to and be enforceable by patient engagement and advocacy functions in Research, Development and Commercial and all its Affiliates, provided that Company shall remain fully liable for the performance of its obligations under this Agreement, including those performed by its Affiliates.

2.2 The Consultant shall provide the Services to the Company as outlined in Appendix 1. Consultant agrees that it:

(i) shall maintain adequate levels of general liability insurance, as appropriate,

(ii) shall obtain all permits, licenses, consents and/or approvals as necessary [Parties shall use the attached consent form as set forth in Appendix 3.]

(iii) shall comply with all material aspects with applicable laws and regulations in the conduct of the Services and performance of Consultant's obligations hereunder,

(iv) hereby confirms that, as of the Effective Date, neither the Consultant nor any Representative, employee or collaborator has any obligations to any third party, and that no third party has any rights, that would prevent Consultant from fulfilling its obligations under this Agreement, and that during the term, neither Consultant nor any, employee or collaborator will enter into any such agreement without the prior written consent of Company.

3. Fees and expenses

3.1 For the Services rendered under the Agreement, the Consultant shall be compensated in accordance with the terms of payment described under Appendix 1.

3.2 The Company will not reimburse for any expenses incurred in relation to the performance of the Agreement.

3.3 The abovementioned Fees and expenses are considered net of Value Added Tax ("VAT"). The Company will additionally pay VAT as legally required. Consultant shall be responsible for all other taxes and/or any social security charges, as applicable, related to the Fee, unless otherwise agreed between the Parties or stipulated otherwise in the applicable law.

3.4 The Parties acknowledge that the Fees for the Services are reasonable and aligned with the prices requested by professionals on the market for similar professional services taking into account all the contributing factors such as, inter alia, individual expertise and training, complexity of tasks, responsiveness and country of origin, as well as the total time invested (work time and preparatory time) into the Services by Consultant and comply with the industry, regulatory, and ethical guidelines and the relevant national codes of practices applicable to the pharmaceutical industry.

3.5 The Company will ensure transparency of the payments made to the Consultant in accordance with the applicable local and international laws, regulations and Codes of Conduct, in particular the European Federation of Pharmaceutical Industries and Associations (EFPIA) "Code of Practice", and the relevant national codes of practices applicable to the pharmaceutical industry. Should the Consultant be in scope for disclosure according to the applicable codes of practices, disclosure will consist of publication on the Company's website or communication to third parties of the following: payments made under this Agreement, including fees and expenses of the Consultant which the Company has covered, a description of the nature of the support or services provided that is sufficiently complete to enable the average reader to form an understanding of the nature of the support or the arrangement without the necessity to divulge confidential information.

4. Independence and conflict of interest

4.1 The Agreement does not create any relationship of agency, or partnership or employment or joint ventures between the Parties. The Consultant shall exercise its activities under the Agreement as an independent contractor.

4.2 The Parties acknowledge that the Fees shall never constitute in any way an inducement to, or reward for, recommending or taking any decisions favourable or promotional to any products or services of the Company or its Affiliates, or have any influence on the content of any materials authored by or on behalf of the Consultant.

4.3 Wherever disclosure is required or appropriate, the Consultant commits to declare that it is providing Services to the Company whenever it writes, speaks or acts in public about a matter that is the subject of the Agreement and will comply with any other applicable disclosure requirements in relation to the Services being perform under the Agreement. If Consultant prepares materials as part of the Services that are disseminated for an external audience, Consultant will disclose the existence of the relationship with Company with a statement such as "Sponsored by Company" or "Supported by Company", but not the amount of financial remuneration involved.

4.4 The Parties confirm that the Agreement is concluded independently from any business transactions and decisions in relation with the supply or purchase of goods or other services related to the Company.

5. Term and termination

5.1 This Agreement comes into force on the Effective Date and shall remain in effect 2 years following Effective date, unless terminated earlier in accordance with the terms of this Agreement.

5.2 Both Parties shall have the right to terminate this Agreement without cause upon thirty (30) days' prior written notice to the other Party.

6. Confidentiality

6.1 The Parties undertake and agree to keep secret and confidential all Confidential Information.

6.2 Both Parties agree to make reasonable efforts to mark their documents and data as confidential. In case of lack of marking, or in case of orally disclosed information, the receiving Party should make reasonable efforts to clarify with the disclosing Party whether the information is confidential or not.

6.3 Any disclosure of Confidential Information to third parties requires prior written consent of the disclosing Party, except that Company is allowed to share with its representatives and Affiliates without any prior consent of the Consultant. Consultant needs to ensure these persons follow the confidentiality rules of this Agreement.

6.4 The obligations and limitations set forth herein regarding the Confidential Information shall not apply to information which is:

(i) in the public domain other than by a breach of this Agreement on the part of the receiving Party; or

(ii) rightfully received from a third party which has the right and transmits it to the receiving Party without breaching any obligation of confidentiality; or

(iii) rightfully known to the receiving Party without breaching any limitation on use or disclosure prior to receipt of the same from the disclosing Party, as shown by the records of the receiving Party; or

(iv) generally made available to third parties by the disclosing Party without any restriction concerning use or disclosure; or

(v) required to be disclosed by law or by a court of competent jurisdiction or by the rules or regulations of an applicable governmental or taxation or regulatory body or authority to whose jurisdiction the receiving Party is subject.

6.5 After the completion of delivery of Services, termination of this Agreement or whenever the disclosing Party requires it, the receiving Party may be asked to return and/or delete the Confidential Information. The receiving Party may be permitted to retain copies if required to demonstrate compliance with this Agreement or with legal proceedings.

7. Intellectual Property rights

7.1 All information, data and Intellectual Property Rights owned by each Party prior to this Agreement shall remain the property of that Party.

7.2 Unless otherwise agreed between the Parties, the Consultant assigns to the Company all of its Intellectual Property Rights on materials and products developed or prepared for the Company by the Consultant in connection with the Services performed hereunder ("**Results**"). However, the Consultant shall always be free to use the general knowledge, skills and experience and any general ideas, concepts, know-how and techniques that the Consultant has acquired or used in the course of performing the Services, subject to respecting confidentiality obligations under Article 6. Notwithstanding anything to the contrary in this Agreement, Company and its Affiliates shall be entitled to use the Results and the Confidential Information therein for all purposes without any restrictions.

The Consultant guarantees that the above Intellectual Property Rights have not been previously assigned and/or licensed and that it is entirely free to be validly assigned to the Company, without

any liens, encumbrance or pledge whatsoever. This means that no third-party has any rights on the Services.

7.3 Any external use by one of the Parties of the other Party's name, trademark or logo requires prior written consent of the other Party. In case this prior written consent is given, the name, trademark or logo should always be used according to the guidelines of the Consultant or the Company.

8. Liability

8.1 To the extent permitted by law, the Consultant shall not be held liable for the performance of its Services under this Agreement, unless caused by gross negligence or wilful misconduct or omission. It shall not be liable for any indirect or consequential loss or damage incurred by the Company in connection with the activities contemplated in this Agreement (such as a loss of profit or damage to the reputation of the Company, etc.).

9. Data privacy

9.1 Company does not anticipate that personal data will be processed by the Consultant as a result of this Agreement. Should it be necessary for the Consultant to process personal data, the Consultant shall comply with all applicable data privacy laws and, where required, enter into a separate data processing agreement with Company.

9.2 Company is committed to protecting the personal data of Consultant representatives, who are involved in providing the Services, in accordance with applicable data privacy laws and as described in Appendix 2 (Privacy Notice).

9.3 The Parties agree that recordings, videos, and photographs of Consultant representatives may be used by Company for internal training and awareness purposes. Company will seek consent from Consultant representatives to use their data externally, to collect any sensitive/special categories of personal data, or as otherwise required under applicable data privacy laws.

9.4 Consultant representatives shall not share the personal data of other individuals (e.g. their children) unless they have the legal authority to act on their behalf, or the other individuals have agreed to their personal data being shared with Company.

10. Anti-bribery compliance

10.1 The Parties undertake to comply with any applicable anti-bribery regulations and codes relating to anti-bribery and anti-corruption (the “Anti-Bribery Laws”), including but not limited to the US Foreign Corrupt Practices Act and the UK Bribery Act 2010. Consultant is prohibited from offering or paying directly or indirectly anything of value to a government official or any other person, entity or institution covered under the Anti-Bribery Laws in order to:

(i) win or retain business for Company;

(ii) improperly influence an act or decision that will benefit Company;

(iii) gain an improper advantage for Company.

Consultant undertakes to keep accurate and transparent records to reflect transactions and payments. Should Consultant breach or have any reason to believe that it might have breached

this section, it shall inform Company immediately, in writing, and cooperate with Company to investigate and document the facts.

10.2 Consultant will notify Company if Consultant attains a position to influence purchasing decisions of a government entity of health-care-related institution (including a hospital, health board or any other institution of a similar nature). Such purchasing decisions may relate, for instance, to tenders issued by health authorities or decisions of formulary committees of public hospitals. In case of such notification by the Consultant, Company has the right to terminate this Agreement with immediate effect by written notice. Consultant shall also notify the purchase decision-maker in said institution of the Consultant's financial relationship with Company before any purchasing decision is made.

11. Entire Agreement

11.1 The Agreement constitutes the entire agreement between the Parties, and supersedes and replaces any prior or contemporaneous communications, representations or agreements between the Parties, whether express or implied, oral or written, including all previous agreements with regard to the subject matter of the Agreement, as well as all negotiations, conversations and discussions between the Parties. The Parties will therefore not be able to derive any rights from prior agreements.

11.2 Any amendment to the Agreement may be made only in writing and by mutual agreement between the Parties.

12. Disputes

12.1 This Agreement shall be governed by and construed in accordance with the laws of Switzerland.

12.2 Any dispute arising in connection with the Agreement which cannot be settled amicably mediation shall be submitted to the exclusive jurisdiction of the courts of the country in which the defendant has its main registered office as to the Company and its main registered office in case the Consultant is acting as a legal entity or of the country in which the Consultant has its residence in case the Consultant is acting as a physical person.

NOVARTIS

The Parties agree to execute this Agreement by their duly authorised representatives.

NOVARTIS PHARMA AG

Signed DocuSigned by: Susan Frade 90039F86104B4E8...

Name Susan Frade

Title Senior Patient Engagement Manager

Date 18-Feb-2025 | 1:51:23 AM PST

NOVARTIS PHARMA AG

Signed DocuSigned by: Monia Steenackers D3DC78BA7BD343A...

Name Monia Steenackers

Title Global Director, Patient Engagement

Date 18-Feb-2025 | 4:45:15 AM PST

LUNG CANCER PATIENT ASSOCIATION

Signed Signed by: Lisbeth Hansen BF9BAA7ECA9840D...

Name Lisbeth Hansen

Title Chairman

Date 17-Feb-2025 | 9:37:16 AM PST

LISBETH HANSEN

Signed Signed by: Lisbeth Hansen BF9BAA7ECA9840D...

Name Lisbeth Hansen

Title Chairman

Date 17-Feb-2025 | 9:37:16 AM PST

Appendix 1: Description of the Services and Financial terms

Appendix 2: Privacy Notice

Appendix 3: Consent form for the use of Personal Data

NOVARTIS

Appendix 1: Description of the Services and the Financial terms

This order is issued in accordance with the Agreement effective on the Effective Date as executed by the Parties.

I. Term

Start Date: February 14, 2025
End date: December 31, 2025

II. Description of the assignment

Project Description: Lung Cancer Patient organizations, including individual patient experts who understand the needs and perspectives of patients with Lung Cancer will provide consultation to Novartis on clinical/education/awareness activities in Oncology. Patient advocates who are representatives of the patient organizations will share the patient and community perspective with Novartis clinical development programmes across Patient Engagement strategy. They will also review and provide feedback on patient education and support programs and activities in these disease areas. Examples of the scope of projects include providing the patient perspective on:

- Review of clinical trial protocols for pipeline assets for treating SCLC and NSCLC.

- Review of patient-facing clinical materials for RLT trials in SCLC and NSCLC

- Patient experience in SCLC and NSCLC

- Patient experience in 1st line combination therapy in SCLC and NSCLC

- Review of plain language summaries of published/presented data

- Clinical Trial informed consent

- Plain language/visual trial summaries associated with new clinical data

- Summary of information for Patients (SIP)

- Patient and caregiver journey – input on research questionnaires and reflections on research findings

- Patient and/or caregiver journey materials, disease education, and awareness campaigns

- Patient/public surveys

- Legal, personal data protection aspects

- Patient outcome data/patient-based evidence efforts

- Patient voice and perspective on the study findings

- Publications of patient data

NOVARTIS

III. Financial terms

In consideration for the Services performed under this Agreement, Company agrees to pay the Consultant a fee in the amount of DKK 1381 (One Thousand Three Hundred and Eighty-One Danish Krone)/ **USD 190.62 (One Hundred and Ninety point Six Two US Dollars)** per completed working hour, plus VAT, if applicable. The maximum amount payable by Company for the Services provided under this agreement is DKK 27620 (Twenty Thousand Six Hundred and Twenty Danish Krone)/ **USD 3812.4 (Three Thousand One Hundred and Twelve point Four US Dollars).**

Invoicing and payment conditions:

(a) The Consultant's invoice shall be paid by bank transfer within 30 days after receipt of a valid invoice.
(b) The Company shall only pay for invoices which request for payment to be made into the entity's official bank account (i.e., not one which is affiliated with an individual), which must be located in the country where the entity is registered. The contracting party will be paid the Patient Organization representative rate for the no. of hours of service provided by the Representative.
(c) The invoices must include the following information:
  (i) Consultant's name and address
  (ii) A detailed description and breakdown of the Services and the date(s) of performance of the Services
  (iii) Amount payable (the invoice shall show one figure for the fees and one figure for the expenses)
  (iv) The details of the Consultant's bank account in the Consultant's country of residence or registration, e.g.:
    - Account number & Routing (ABA) Code for **US Consultants**; or IBAN & Swift Code for **European Consultants**
  (v) Consultant VAT number (if applicable)
  (vi) Novartis VAT number (CHE-116.268.023)
  (vii) Consultant's social tax number (AHV) if Consultant is a Swiss resident
  (viii) Novartis contact person
  (ix) Purchase Order (PO) number received from Novartis (if applicable)

(d) The invoice(s) must be sent to the following address:

Novartis Pharma AG
Zentraler Faktureneingang
PO Box
4002 Basel
Switzerland

Name of Novartis contact: **Gifty Cobby Amporful** gifty.cobby_amporful@novartis.com **and eso.patient-engagements@novartis.com.**

(e) The payment will be executed as per the below banking information:

Bank Name	Danske Bank
Bank Address	København
Account Holder Name	Lisbeth Joan Søbæk Hansen

Account Number	0274 4515869212
IBAN Number	DK7130004515869212
SWIFT Code	DABADKKK
Routing Number	0274 4515869212
Others (If any)	NO

The Company shall directly, or through a designated and authorised third party agent responsible for settlement of payments, pay fees and expenses as may be notified by Company's contact.

NOVARTIS

Appendix 2: Privacy Notice

Novartis is responsible for the processing of your personal data as it decides why and how it is processed, thereby acting as the "controller". In this Privacy Notice, "we" or "us" refers to Novartis Pharma AG.

If you are sharing the personal data of another individual, with legal authority or with their agreement, references to "you" and "your" also refer to the other individual.

1 What personal data will we process?

Novartis will process the personal data necessary to perform the Services under this Agreement, which includes your name, contact details, and payment information (if applicable).

2 For which purposes will we use your personal data and why is this justified?

2.1 Legal basis for the processing

We will not process your personal data if we do not have a proper justification foreseen in the law for that purpose. Therefore, we will only process your personal data if:

- the processing is necessary for the performance of a contract – such as the performance of its Services under this Agreement;
- we have obtained your prior consent – such as when we ask you to use your personal data externally, in which case we will ask you to sign a separate consent form;
- the processing is necessary to comply with our legal or regulatory obligations – such as pharmacovigilance legislation and regulatory code compliance; or
- the processing is necessary to protect your vital interests or those of another person – if necessary for the purpose of drug safety.

2.2 Purposes of the processing

We always process your personal data for a specific purpose, and only process the personal data which is relevant to achieve that purpose. In addition to the specific purposes identified in the Agreement, please note that personal data may also be used for the following general purposes:

- answer any questions or requests you may have;
- for pharmacovigilance purposes (tracking of side effects);
- manage our IT resources, including infrastructure management and business continuity;
- preserve the company's economic interests and ensure compliance and reporting (such as complying with our policies and local legal requirements, tax and deductions, managing alleged cases of misconduct or fraud, conducting audits and defending litigation);
- manage mergers and acquisitions involving our company;
- archiving and record-keeping; and
- any other purposes imposed by law and authorities.

3 Who will have access to your personal data and to whom will they be transferred?

We will not sell, share, or otherwise transfer your personal data to third parties other than those specified in this Privacy Notice. In the course of our activities and for the same purposes as those outlined in this Privacy Notice, your personal data can be accessed by, or transferred to the following categories of recipients, on a need to know basis to achieve such purposes:

- our personnel (including personnel, departments or other companies of the Novartis group);
- our independent agents or brokers (if any);
- our suppliers and services providers that provide services and products to us;
- our IT systems providers, cloud service providers, database providers and consultants;

- our business partners who offer products or services jointly with us or with our subsidiaries or affiliates;
- any third party to whom we assign or novate any of our rights or obligations; and

The above third parties are contractually obliged to protect the confidentiality and security of your personal data, in compliance with applicable law.

Your personal data can also be accessed by or transferred to any national and/or international regulatory, enforcement, public body or court, where we are required to do so by applicable law or regulation or at their request.

The personal data we collect from you may also be processed, accessed or stored in a country outside the country where Novartis is located, which may not offer the same level of protection of personal data. If we transfer your personal data to external companies in other jurisdictions, we will make sure to protect your personal data by (i) applying the level of protection required under the local data protection/privacy laws applicable to Novartis Pharma AG, (ii) acting in accordance with our policies and standards and, (iii) for entities located in the European Economic Area (i.e. the EU Member States plus Iceland, Liechtenstein and Norway, the "EEA"), unless otherwise specified, only transferring your personal data on the basis of standard contractual clauses approved by the European Commission. You may request additional information in relation to international transfers of personal data and obtain a copy of the adequate safeguard put in place by exercising your rights as set out below.

For intra-group transfers of personal data, the Novartis group has adopted Binding Corporate Rules, a system of principles, rules and tools, provided by European law, in an effort to ensure effective levels of data protection relating to transfers of personal data outside the EEA and Switzerland. Read more about the Novartis Binding Corporate Rules at novartis.com/privacy.

4 How do we protect your personal data?

We have implemented appropriate technical and organisational measures to provide a level of security and confidentiality to your personal data. These measures take into account: the state of the art of the technology; the costs of its implementation; the nature of the data; and the risk of the processing. The purpose of these measures is to protect it against accidental or unlawful destruction or alteration, accidental loss, unauthorised disclosure or access and against other unlawful forms of processing.

5 How long do we store your personal data?

We will only retain your personal data for as long as necessary to fulfil the purpose(s) for which it was collected or to comply with legal or regulatory requirements.

6 What are your rights and how can you exercise them?

You have a right to request a copy of the personal information we hold about you. You may also object to its use or ask for it to be updated, restricted, deleted, or transferred to another organisation.

If you have a question or want to exercise the above rights, please contact us at gifty.cobby_amporful@novartis.com. If you are not satisfied with how we process your personal data, please address your request to our Data Protection Officer at global.privacy_office@novartis.com, who will investigate your concern.

In any case, you also have the right to file a complaint with a supervisory authority, in addition to your rights above.

7 How will you be informed of the changes to our Privacy Notice?

Any future changes or additions to the processing of your personal data as described in this Privacy Notice will be notified to you in advance through an individual notice through our usual communication channels (e.g. by email or via our websites).

NOVARTIS

Appendix 3: Consent Form

This consent form ("Consent Form") forms part of the attached Advisory board agreement (the "Agreement") between you and Novartis Pharma AG. In this Consent Form, "Novartis" "we" or "us" refers to Novartis Pharma AG

You have been provided with this Consent Form because Novartis would like to collect additional information about you ("personal data") and/or use your personal data for additional purposes.

If you are providing consent on behalf of another individual, where you have the legal authority to act on their behalf, references to "you", "your", "my", and "I" refer to the other individual.

The scope of this Consent Form is limited to the purposes described below. This Consent Form should be read in conjunction with the Privacy Notice attached to the Agreement ("Privacy Notice"). A copy of the Privacy Notice is available on request.

What additional personal data will Novartis collect from me?

- Medical/health information (including diagnosis information, sharing experience of a health condition)
- Full name and contact information (phone, address, email address).

Which additional third parties will Novartis share my personal data with?

For the purposes described in this Consent Form, we will share your personal data with the following specific third parties:

- anne.olshan@olshanpr.com

How long will my personal data be stored?

For the purposes described in this Consent Form, we will store your personal data for a period of seven years after the service has been provided, unless a different term has been agreed.

Can I withdraw my consent?

You have the right to withdraw your consent at any time by writing to us at gifty.cobby_amporful@novartis.com. This will not affect the lawfulness of any processing carried out by Novartis before you withdraw your consent.

Which purposes will my personal data be used for?

On the basis of your consent, Novartis will process your personal data for the purposes described in this Consent Form (in addition to the purposes described in the Agreement). Please note that we may edit media (e.g. photos, videos, audio recordings), or combine them with other written, printed, graphic, or recordings. We may edit, summarise, and rephrase any statements you make; however, we will not change their meaning.

I consent to the following non-public uses (within Novartis) of the personal data described above:

- Education or training for Novartis associates, within Novartis or Novartis' Group companies

I acknowledge that I have read and understood this Consent Form and the Privacy Notice. I am providing my consent for Novartis to use my personal data for the purposes stated above, and I am providing my consent voluntarily. I acknowledge that I have had the opportunity to have all of my questions answered to my satisfaction.